Clarity Pharmaceuticals (CU6) Q3 2026 TU earnings summary

Executive summary

• Progress toward commercial launch with robust clinical trial advancement and supply chain expansion.

• Recruitment closed for the pivotal AMPLIFY Phase III trial; CLARIFY Phase III trial recruitment ongoing.

• Strong clinical data from Co-PSMA Phase II trial, showing superior diagnostic performance over standard-of-care.

• SECURE Phase II trial demonstrates promising efficacy and safety for 67Cu-SAR-bisPSMA therapy in mCRPC.

• Strengthened executive team and board to support commercialisation and governance.

Financial highlights

• Cash balance at 31 March 2026: $197.8 million.

• Net operating cash outflows for the quarter: $25.5 million, consistent with prior quarter.

• $1.4 million invested in manufacturing readiness during the quarter.

• Estimated funding runway of 8 quarters based on current cash and burn rate.

Outlook and guidance

• Well-funded to support ongoing clinical trials and commercial rollout.

• Anticipates completion of CLARIFY trial recruitment in 2026.

• Preparing for regulatory submissions to the US FDA for 64Cu-SAR-bisPSMA based on AMPLIFY and CLARIFY data.